Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

• Published in: Advances in therapy Vol. 38; no. 11; pp. 5465 - 5483
• Main Authors: Reuter, Uwe, Lucas, Christian, Dolezil, David, Hand, Austin L., Port, Martha D., Nichols, Russell M., Stroud, Chad, Tockhorn-Heidenreich, Antje, Detke, Holland C.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.11.2021
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Cardiology; Endocrinology; Humans; Internal Medicine; Medicine; Medicine & Public Health; Middle Aged; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; NCT; NCT03559257; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Treatment Outcome; Young Adult; Chronic migraine; Episodic migraine; Treatment failure; Galcanezumab; Monoclonal antibody; CGRP; Elderly; Migraine preventive

Introduction Results from the open-label extension of the phase 3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, for up to 6 months in patients with multiple prior migraine preventive treatment f...